GVIRF2023

World Health Organization, Geneva

Investigators

Linked publications & trials

Abstract

Program Director/Principal Investigator (Last, First, Middle): Friede, Martin, H PROJECT SUMMARY (See instructions): The World Health Organization (WHO), the Bill and Melinda Gates Foundation (BMGF) and the National Institute of Allergy and Infectious Diseases (NIAID) signed a MOU to collaborate on carrying out the objectives of the Global Vaccine Action Plan (GVAP). GVAP was developed to achieve the vision of the Decade of Vaccines of Collaboration in extending the full benefits of immunization to all people, regardless of where they were born or where they live. In 2020, GVAP was replaced by IA2030 where the Global Vaccine and Immunization Research Forum (GVIRF) became a key component of the Strategic Priorities 7 (SP7).The GVIRF serves as a scientific forum that: 1) review the SP7 R&D agenda progress; 2) track progress and discuss obstacles related to priority vaccine research and development; 3) identify actions recommended to be taken by the research and development community in the area of vaccines and immunization research, and; 4) create an opportunity for networking among the vaccine research and immunization community. The first GVIRF was held on 14-16 March 2014 in Bethesda, MD, USA, the 2nd Forum was held on 15-17 March 2016 in Johannesburg, South Africa and the 3rd Forum was held 20-22 March 2018 in Bangkok, Thailand. The 4th Forum was expected in Seoul, Republic of Korea, in March 2020, but had to be cancelled due to the Covid-19 pandemic and instead a virtual Forum took place in February 2021. An in-person forum is scheduled to take place in March 2023 in either Seoul, Republic of Korea. The Forum is co-sponsored by the Bill & Melinda Gates Foundation and NIAID, with contribution from WHO in kind for the organization and execution of the meeting. RELEVANCE (See instructions): IVIR-AC meeting conclusions will be reported by the IVIR-AC Chair to SAGE. At the same time IVIR-AC will review outcomes of SAGE meetings and decisions in order to complement and support the work of SAGE. PROJECT/PERFORMANCE SITE(S) (if additional space is needed, use Project/Performance Site Format Page) Project/Performance Site Primary Location Organizational Name: World Health Organization DUNS: 480997543 Street 1: Avenue Appia 20 Street 2: City: Geneva County: State: Province: Country: Switzerland Zip/Postal Code: 1211 Project/Performance Site Congressional Districts: Additional Project/Performance Site Location Organizational Name: TBD DUNS: Street 1: Street 2: City: Seoul County: State: Province: Country: Republic of Korea Zip/Postal Code: Project/Performance Site Congressional Districts: PHS 398 (Rev. 01/18 Approved Through 03/31/2020) OMB No. 0925-0001 Page 2 Form Page 2 Program Director/Principal Investigator (Last, First, Middle): SENIOR/KEY PERSONNEL. See instructions. Use continuation pages as needed to provide the required information in the format shown below. Start with Program Director(s)/Principal Investigator(s). List all other senior/key personnel in alphabetical order, last name first. Name eRA Commons User Name Organization Role on Project Friede, Martin WHO PI OTHER SIGNIFICANT CONTRIBUTORS Name Organization Role on Project Human Embryonic Stem Cells No Yes If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the following list: https://grants.nih.gov/stem_cells/registry/current.htm. Use continuation pages as needed. If a specific line cannot be referenced at this time, include a statement that one from the Registry will be used. Cell Line PHS 398 (Rev. 01/18 Approved Through 03/31/2020) OMB No. 0925-0001 Page 3 Form Page 2-continued Number the following pages consecutively throughout the application. Do not use suffixes such as 4a, 4b.